The pharmaceutical manufacturing industry rewards those who understand it from the inside — the mechanics of sterile fill-finish, the nuances of FDA inspection cycles, the complexity of API supply chains. Parami’s edge is that we have lived this.
When we acquire a company, we don’t send consultants — we deploy experienced operators who sit alongside management, make decisions, and are accountable for outcomes.
Strengthening governance, compliance, and operational discipline
From day one — ensuring business continuity, regulatory standing, and immediate operational stability across the acquired platform.
Implementing cost structure improvements, manufacturing efficiency programmes, quality system upgrades, and supply chain restructuring.
Building manufacturing capacity, advancing product pipelines, and entering new regulated markets to capture commercial growth opportunities.
Building systems and leadership for long-term durability
Developing leadership teams, management systems, and governance processes required to support long-term scalability as a standalone platform.
Sterile manufacturing, aseptic processing, lyophilisation, fill-finish, and complex oral solid dosage — deep technical knowledge and unit economics across every modality.
FDA, EMA, and WHO navigation — remediation, new filings, technology transfers, inspection management, and compliance programme design and execution.
Global API and excipient sourcing, vendor qualification, demand planning, and logistics structured for resilience, cost efficiency, and continuity of supply.
Pricing strategy, tender management, customer relationships, and channel partnerships for hospital, retail, and institutional pharmaceutical markets globally.
End-to-end transaction execution for carve-outs, platform acquisitions, and bolt-ons — including diligence, structuring, regulatory continuity, and 100-day integration.
Building world-class pharmaceutical leadership teams from our deep industry network with incentive structures aligned to long-term value creation.